VERANDA™-SSc: Design of a Phase III, Double-blind, Randomized, Placebo-controlled Trial Evaluating the Safety and Efficacy of Oral Nerandomilast Treatment on Halting Disease Progression in Systemic Sclerosis (ACR Convergence 2026) - Sep 8, 2026 - Abstract #2905; Pres time: Nov 10, 2026; 03:30 PM - 03:45 PM; Location: W304A-H; In Person; "Patients will be stratified by SSc subtype, presence of ILD, and concomitant use of mycophenolate, nintedanib, both, or neither. The VERANDA™-SSc trial is a novel time-to-event-driven Phase III study evaluating the efficacy and safety of nerandomilast in patients with SSc, a disease for which there are no widely licensed pharmacological treatments targeting overall disease progression."
Clinical • P3 data • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases • Scleroderma • Suicidal Ideation • Systemic Sclerosis • Vasculitis
|
|
Anna-Maria Hoffmann-Vold 1; Oliver Distler 2; Yannick Allanore 3; Francesco Del Galdo 4; Christopher Denton 5; Masataka Kuwana 6; Dinesh Khanna 7; Zsuzsanna McMahan 8; Elizabeth Volkmann 9; Martina Gahlemann 10; Hao Li 11; Susanne Stowasser 12; and Shervin Assassi 13
|